PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis
Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with high affinity, based on the VEGFR1 backbone. Here, we elucidated PB101-induced...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2259212 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102318397784064 |
|---|---|
| author | Eun-Jin Go Hannah Yang Seung Joon Lee Hyun Gul Yang Jin A. Shin Won Suk Lee Hye Seong Lim Hong Jae Chon Chan Kim |
| author_facet | Eun-Jin Go Hannah Yang Seung Joon Lee Hyun Gul Yang Jin A. Shin Won Suk Lee Hye Seong Lim Hong Jae Chon Chan Kim |
| author_sort | Eun-Jin Go |
| collection | DOAJ |
| description | Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with high affinity, based on the VEGFR1 backbone. Here, we elucidated PB101-induced remodeling of tumor angiogenesis and immunity, which enhances anti-PD-L1 immune checkpoint blockade. PB101 inhibited tumor growth by suppressing angiogenesis and enhancing CD8+ T cell infiltration into the tumors. PB101 induced robust reprogramming of antitumor immunity and activates intratumoral CD8+ T cells. Anti-tumor efficacy of PB101 is mostly dependent on CD8+ T cells and IFN-γ. PB101 reprograms tumor immunity in a manner distinct from that of the conventional VEGF decoy receptor, VEGF-trap. With its potent immune-modulating capability, PB101 synergizes with an anti-PD-L1, triggering strengthened antitumor immunity. Combining PB101 and anti-PD-L1 could establish durable protective immunity against tumor recurrence and metastasis. The findings of this study offer scientific rationales for further clinical development of PB101, particularly when used in combination with immune checkpoint inhibitors, as a potential treatment for advanced cancers. |
| format | Article |
| id | doaj-art-f42cb26890c74ee3a1d1cfa3398077e0 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-f42cb26890c74ee3a1d1cfa3398077e02024-12-27T17:34:38ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2259212PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasisEun-Jin Go0Hannah Yang1Seung Joon Lee2Hyun Gul Yang3Jin A. Shin4Won Suk Lee5Hye Seong Lim6Hong Jae Chon7Chan Kim8Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaMedical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaMedical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaPanolos Bioscience, Inc, Hwaseong-si, Republic of KoreaPanolos Bioscience, Inc, Hwaseong-si, Republic of KoreaMedical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaPanolos Bioscience, Inc, Hwaseong-si, Republic of KoreaMedical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaMedical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Gyeonggi-do, Republic of KoreaAntiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with high affinity, based on the VEGFR1 backbone. Here, we elucidated PB101-induced remodeling of tumor angiogenesis and immunity, which enhances anti-PD-L1 immune checkpoint blockade. PB101 inhibited tumor growth by suppressing angiogenesis and enhancing CD8+ T cell infiltration into the tumors. PB101 induced robust reprogramming of antitumor immunity and activates intratumoral CD8+ T cells. Anti-tumor efficacy of PB101 is mostly dependent on CD8+ T cells and IFN-γ. PB101 reprograms tumor immunity in a manner distinct from that of the conventional VEGF decoy receptor, VEGF-trap. With its potent immune-modulating capability, PB101 synergizes with an anti-PD-L1, triggering strengthened antitumor immunity. Combining PB101 and anti-PD-L1 could establish durable protective immunity against tumor recurrence and metastasis. The findings of this study offer scientific rationales for further clinical development of PB101, particularly when used in combination with immune checkpoint inhibitors, as a potential treatment for advanced cancers.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2259212Angiogenesiscombination immunotherapyimmune checkpoint inhibitorPB101PlGFtumor immunity |
| spellingShingle | Eun-Jin Go Hannah Yang Seung Joon Lee Hyun Gul Yang Jin A. Shin Won Suk Lee Hye Seong Lim Hong Jae Chon Chan Kim PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis OncoImmunology Angiogenesis combination immunotherapy immune checkpoint inhibitor PB101 PlGF tumor immunity |
| title | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| title_full | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| title_fullStr | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| title_full_unstemmed | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| title_short | PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis |
| title_sort | pb101 a vegf and plgf targeting decoy protein enhances antitumor immunity and suppresses tumor progression and metastasis |
| topic | Angiogenesis combination immunotherapy immune checkpoint inhibitor PB101 PlGF tumor immunity |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2259212 |
| work_keys_str_mv | AT eunjingo pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT hannahyang pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT seungjoonlee pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT hyungulyang pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT jinashin pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT wonsuklee pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT hyeseonglim pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT hongjaechon pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis AT chankim pb101avegfandplgftargetingdecoyproteinenhancesantitumorimmunityandsuppressestumorprogressionandmetastasis |